Should I Buy DARE? DARE 2026 Analysis

Should You Buy Dare Bioscience Inc (DARE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.680

1 Day change

-5.08%

52 Week Range

9.190

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: trend is firmly bearish (SMA_200 > SMA_20 > SMA_5) with weakening momentum (MACD histogram below 0 and negatively expanding).
No proprietary buy signals today (AI Stock Picker and SwingMax both show no signal), so there’s no tactical “must-buy” trigger.
Financial momentum is poor (2025/Q3 revenue down ~95% YoY; losses continue), and there are no near-term news catalysts to change sentiment.
For an impatient investor who doesn’t want to wait for better entries, the setup is unfavorable; avoid/exit rather than trying to bottom-fish.

Technical Analysis

Price/trend: Bearish structure with stacked negative moving averages (SMA_200 > SMA_20 > SMA_5), indicating persistent downtrend.
Momentum: MACD histogram -0.0216 and getting more negative → bearish momentum strengthening.
RSI: RSI_6 ≈ 23.16 → oversold conditions; a short-term bounce is possible, but oversold can persist in downtrends.
Levels: Pivot 1.87 (overhead), resistance at 1.985 then 2.055; support at 1.756 then 1.685. Current price 1.73 is below S1 (1.756), which is technically weak.
Pattern-based expectation: Similar-pattern stats imply slightly negative bias near-term (next day -0.48%, next week -0.37%) with only modest positive skew over a month (+0.84%).
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Positive Catalysts

- Oversold RSI could fuel a short-lived technical bounce if buyers defend the 1.685–1.756 support zone.
- No heavy hedge-fund/insider selling trend indicated recently (both neutral), which slightly reduces “forced selling” risk.

Neutral/Negative Catalysts

- Clear downtrend with bearish momentum (MACD worsening) and price trading below key support (S1 1.756).
- No news/catalysts in the last week to change the narrative or attract new demand.
- Similar-pattern outlook tilts mildly negative over the next day/week.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 2,262, down -94.57% YoY → severe top-line contraction.
Net income: -3,562,766 (loss), down -24.24% YoY (worse).
EPS: -0.28, down -49.09% YoY (worse).
Gross margin: 100% (likely not meaningful given extremely low revenue base); overall fundamentals still deteriorating.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so there’s no visible Wall Street upgrade/downgrade trend to support a near-term bull case.
Wall Street-style pros (based on available data): oversold technical condition could allow a bounce.
Wall Street-style cons (based on available data): collapsing revenue and ongoing losses + bearish chart + lack of catalysts.

2 Analyst Rating

Wall Street analysts forecast DARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DARE is 10 USD with a low forecast of 8 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.770

Low

Averages

High

Current: 1.770

Low

Averages

High

Maxim

Jason McCarthy

Hold

Buy

upgrade

AI Analysis

2025-09-04

Reason

Maxim

Jason McCarthy

Price Target

AI Analysis

2025-09-04

upgrade

Hold

Buy

Reason

Maxim analyst Jason McCarthy upgraded Dare Bioscience to Buy from Hold with an $8 price target.

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$12

2025-04-01

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$12

2025-04-01

Reiterates

Strong Buy

Reason

DARE Should I Buy

DARE Should I Buy

Should You Buy Dare Bioscience Inc (DARE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch